Roche's (RHHBY) RoActemra Gets EU Approval for Early RA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 4:20PM CDT
Positive news flowed in at Roche (RHHBY) when its RA drug RoActemra received approval from the European Commission to treat patients suffering from early RA who have previously not been treated with methotrexate (MTX).
AbbVie (ABBV) Marked As A Barbarian At The Gate
at The Street - Tue Sep 09, 12:23PM CDT
Trade-Ideas LLC identified AbbVie (ABBV) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Uveitis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 30 Drug Profiles
M2 - Tue Sep 09, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cv63wn/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - pSivida Corp. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Apitope International NV - Novartis AG - Pfizer Inc. - Enzo Biochem, Inc. - Can-Fite BioPharma Ltd. - XOMA Corporation - HanAll Biopharma Co., Ltd. - TxCell SA - Endocyte, Inc. - to-BBB technologies BV - Janssen Biotech, Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - AbbVie Inc. - OncoNOx ApS - Panoptes Pharma Ges.m.b.H. Drug Profiles - sirolimus - adalimumab - fluocinolone acetonide - gevokizumab - secukinumab - CF-101 - triamcinolone acetonide - LFG-316 - B27-PD - triamcinolone acetonide - celecoxib - HL-036 - EC-1496 - PA-2612 - 2B3-201 - ATX-UV1 - ATX-UV2 - Stem Cell Therapy for Ophthalmic and Autoimmune Diseases - OX-1001 - P-13 - IBI-70090 - plastoquinone decyl triphenylphosphonium bromide - EC-1669 - lodamin - PP-001 - INV-17 - EBI-028 - Col-Treg - Small Molecules to Inhibit Kinase for Uveitis and IBD - Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Metabolic, Respiratory and Autoimmune Disorders For more information visit http://www.researchandmarkets.com/research/cv63wn/uveitis
Pharmacyclics Price Target Cut On Higher Spending
at Investor's Business Daily - Mon Sep 08, 12:02PM CDT
Biotech Pharmacyclics (PCYC) got a price-target cut from Nomura on Monday, but the investment bank maintained a buy rating on Pharmacyclics stock, saying the company's competitive position remains strong. Pharmacyclics stock was flat in midday...
FTC Sues Pharmaceutical Companies for Illegally Blocking Consumer Access to Lower-Cost Versions of the Blockbuster Drug AndroGel
PR Newswire - Mon Sep 08, 11:50AM CDT
In its latest action to ensure competition in the nation's healthcare markets, the Federal Trade Commission has filed a complaint in federal district court charging several major pharmaceutical companies with illegally blocking American consumers' access to lower-cost versions of the blockbuster drug AndroGel.
Will Google and AbbVie’s $1.5 Billion Anti-Aging Partnership Pay Off?
Leo Sun, The Motley Fool - Motley Fool - Sat Sep 06, 6:05AM CDT
Google 's health care footprint just got a lot bigger, thanks to a new $1.5 billion partnership between its biotech unit Calico and drug maker AbbVie . Source: Wikimedia Commons. Calico, which is headed by former Genentech CEO Arthur...
Abbott Labs' FreeStyle Libre Flash Glucose Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:35PM CDT
Abbott Labs (ABT) received positive news when its FreeStyle Libre Flash Glucose Monitoring System obtained CE Mark (Conformite Europeenne) in Europe.
Why Gilead Is Falling On Drugs For Developing Nations
at Investor's Business Daily - Fri Sep 05, 2:15PM CDT
Shares of Gilead Sciences (GILD) are down amid news that the drugmaker is reportedly nearing a licensing deal to bring its blockbuster hepatitis C drug Sovaldi to developing countries such as India and Pakistan. Generic drugmakers would be able to...
Treasury Secretary's Upcoming Inversion Talk to Widen Spreads
at The Street - Fri Sep 05, 8:21AM CDT
The Treasury Secretary Jack Lew is expected to opine on tax inversions next week, a subject that has been a major issue for risk arbitrage spreads.
AbbVie to Present at Morgan Stanley Global Healthcare Conference
PR Newswire - Fri Sep 05, 7:00AM CDT
AbbVie (NYSE: ABBV) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 10, 2014. Bill Chase, executive vice president and chief financial officer, will make a formal presentation on the company at 9:20 a.m. Central time.
Will AbbVie's $805 Million Agreement for Duvelisib Pay Off? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 4:10PM CDT
In order to boost its pipeline, AbbVie (ABBV) inked a collaboration agreement with Infinity Pharmaceuticals (INFI).
3 Reasons Bristol-Myers Squibb's Stock Could Fall
George Budwell, The Motley Fool - Motley Fool - Thu Sep 04, 3:42PM CDT
This has been a year of major changes for Big Pharma. As the so-called patent cliff has started to peak, we've seen a number of companies make huge acquisitions, push promising new drugs into regulatory review, and even move to change locales to...
Google's Calico in $500M Joint Venture with AbbVie - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 3:38PM CDT
Calico, Google's (GOOGL) year-old health startup is collaborating with biotechnology drugmaker, AbbVie, a spin-off from Abbott Laboratories (ABT), for a joint venture to formulate treatments for cancer and Alzheimer's.
Upcoming Event, Drug Approval, Technical Updates, and Research Grant - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Thermo Fisher
PR Newswire - Thu Sep 04, 8:20AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Express Scripts Holding Company (NASDAQ: ESRX) and Thermo Fisher Scientific Inc. (NYSE: TMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6210-100free.
3 Reasons Gilead Sciences, Inc.’s Stock Could Fall
Brian Orelli, The Motley Fool - Motley Fool - Thu Sep 04, 7:31AM CDT
Gilead Sciences ' stock is a trading at all-time highs, up more than 80% over the last year on the back of a very successful launch of the company's hepatitis C drug Sovaldi. A few weeks ago, I shared three reasons Gilead's stock could go even...
Biotech Advancements in Innovative Cancer Therapy Reveal Developing Systemic Treatment Options - Company Receives Recommendation from World Health Organization for Lead Drug Candidate
PR Newswire - Thu Sep 04, 7:15AM CDT
Biotech companies seeking to make progress with Hepatocellular Carcinoma (HCC) therapies and other cancer therapeutics: GenSpera Inc. (OTC: GNSZ), Roche Holding AG (OTC: RHHBY), Eli Lilly and Company (NYSE: LLY), Amgen Inc. (NASDAQ: AMGN), Johnson and Johnson (NYSE: JNJ) and Infinity Pharmaceuticals Inc. (NASDAQ: INFI)
Infinity Pharma (INFI) Shares Skyrocket on Cancer Drug Partnership - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Wed Sep 03, 5:47PM CDT
Shares of Infinity Pharma (INFI) are up more than 40 percent thanks to news of a partnership with AbbVie for a new cancer drug.
Infinity, AbbVie team on drug
at Investor's Business Daily - Wed Sep 03, 5:36PM CDT
Small biotech Infinity Pharmaceuticals (INFI) agreed to develop its blood cancer drug duvelisib, currently in trial stage, with big pharma AbbVie (ABBV). The deal includes an upfront payment of $275 mil to Infinity, and up to $530 mil in milestone...
Revised GAAP earnings guidance for AbbVie Inc for the Financial Year ending December 31, 2014 and Third Quarter ending September 30, 2014; Confirms Adjusted Earnings Guidance
PR Newswire Europe - Wed Sep 03, 3:46PM CDT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION